Effect of Nocturnal Administration of Anti-hypertensive Medications in NoN-dippers
Primary Purpose
Hypertension
Status
Completed
Phase
Phase 4
Locations
Korea, Republic of
Study Type
Interventional
Intervention
Valsaltan, amlodipine
Sponsored by

About this trial
This is an interventional treatment trial for Hypertension focused on measuring Non-dipper HTN patient
Eligibility Criteria
Inclusion Criteria:
- Essential hypertension (stage 1-2)
- 24hr. holer : non-dipper
- Age 18 ~70.
Exclusion Criteria:
- Any known malignant disease
- Renal failure , creatinine >2.0mg/dl
- Liver disease
Sites / Locations
- Severance Hospital, Yonsei University College of Medicine
Arms of the Study
Arm 1
Arm 2
Arm Type
Placebo Comparator
Experimental
Arm Label
morning administration group
nocturnal administration group
Arm Description
Outcomes
Primary Outcome Measures
IMT(intima media thickness) Measure data(Sono)
IMT(intima media thickness) Measure data(Sono)
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01091753
Brief Title
Effect of Nocturnal Administration of Anti-hypertensive Medications in NoN-dippers
Official Title
Effect of Nocturnal Administration of Anti-hypertensive Medications in NoN-dippers
Study Type
Interventional
2. Study Status
Record Verification Date
October 2010
Overall Recruitment Status
Completed
Study Start Date
March 2008 (undefined)
Primary Completion Date
May 2009 (Actual)
Study Completion Date
September 2009 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Yonsei University
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to determine the effect of nocturnal administration of Anti-hypertensive medications in Non-dippers.
Efficacy variables.
ECHO
24hr. horter
IMT
BUN/crea, urine analysis (microalbulinuria
Cardio vascular event. "
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
Keywords
Non-dipper HTN patient
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Masking
None (Open Label)
Allocation
Randomized
Enrollment
28 (Actual)
8. Arms, Groups, and Interventions
Arm Title
morning administration group
Arm Type
Placebo Comparator
Arm Title
nocturnal administration group
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
Valsaltan, amlodipine
Intervention Description
nti hypertensive medication time (nocturnal administration vs morning administration
Primary Outcome Measure Information:
Title
IMT(intima media thickness) Measure data(Sono)
Time Frame
baseline
Title
IMT(intima media thickness) Measure data(Sono)
Time Frame
36 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Essential hypertension (stage 1-2)
24hr. holer : non-dipper
Age 18 ~70.
Exclusion Criteria:
Any known malignant disease
Renal failure , creatinine >2.0mg/dl
Liver disease
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Dong hun Choi
Organizational Affiliation
professor of division of Cardiology
Official's Role
Principal Investigator
Facility Information:
Facility Name
Severance Hospital, Yonsei University College of Medicine
City
Seoul
Country
Korea, Republic of
12. IPD Sharing Statement
Learn more about this trial
Effect of Nocturnal Administration of Anti-hypertensive Medications in NoN-dippers
We'll reach out to this number within 24 hrs